Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Mari Mino-Kenudson, M.D.

Co-Author

This page shows the publications co-authored by Mari Mino-Kenudson and Cristina Ferrone.
Connection Strength

2.341
  1. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Histopathology. 2020 Jul; 77(1):144-155.
    View in: PubMed
    Score: 0.226
  2. Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. Gastroenterology. 2019 09; 157(3):720-730.e2.
    View in: PubMed
    Score: 0.210
  3. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. Ann Surg. 2017 01; 265(1):185-191.
    View in: PubMed
    Score: 0.178
  4. Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. Surgery. 2014 Sep; 156(3):611-21.
    View in: PubMed
    Score: 0.150
  5. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012 Sep; 152(3 Suppl 1):S43-9.
    View in: PubMed
    Score: 0.130
  6. A decrease in preoperative to postoperative CA19-9 level is a significant predictor of survival in patients with pancreatic adenocarcinoma. J Clin Oncol. 2005 Jun; 23(16_suppl):4034.
    View in: PubMed
    Score: 0.080
  7. "Evolving Trends in Pancreatic Cystic Tumors: A 3-Decade Single-Center Experience with 1290 Resections". Ann Surg. 2021 Aug 04.
    View in: PubMed
    Score: 0.061
  8. Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. Ann Surg. 2021 08 01; 274(2):e134-e142.
    View in: PubMed
    Score: 0.061
  9. Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. Pancreatology. 2021 May 15.
    View in: PubMed
    Score: 0.060
  10. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2020 Nov 09.
    View in: PubMed
    Score: 0.058
  11. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Mol Cancer Res. 2020 12; 18(12):1889-1902.
    View in: PubMed
    Score: 0.057
  12. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score. Ann Surg. 2020 Jul 07.
    View in: PubMed
    Score: 0.057
  13. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2020 Oct; 27(10):3898-3912.
    View in: PubMed
    Score: 0.056
  14. An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN. Pancreatology. 2020 Jun; 20(4):729-735.
    View in: PubMed
    Score: 0.056
  15. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020 Jun; 20(4):722-728.
    View in: PubMed
    Score: 0.055
  16. Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma. Ann Surg. 2019 12; 270(6):1138-1146.
    View in: PubMed
    Score: 0.054
  17. Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg. 2018 08; 268(2):340-347.
    View in: PubMed
    Score: 0.050
  18. Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. Ann Surg. 2018 01; 267(1):157-163.
    View in: PubMed
    Score: 0.048
  19. Ductal Carcinoma Arising in a Largely Unchanged Presumed Branch-duct IPMN After 10 Years of Surveillance. Ann Surg. 2017 Dec; 266(6):e38-e40.
    View in: PubMed
    Score: 0.047
  20. Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. J Gastrointest Surg. 2018 02; 22(2):226-234.
    View in: PubMed
    Score: 0.047
  21. Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. Pancreatology. 2017 Nov - Dec; 17(6):920-926.
    View in: PubMed
    Score: 0.047
  22. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 2017; 12(8):e0182855.
    View in: PubMed
    Score: 0.046
  23. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. Gastroenterology. 2017 11; 153(5):1284-1294.e1.
    View in: PubMed
    Score: 0.046
  24. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM. Ann Surg. 2017 07; 266(1):142-148.
    View in: PubMed
    Score: 0.046
  25. Diverse repetitive element RNA expression defines epigenetic and immunologic features of colon cancer. JCI Insight. 2017 02 09; 2(3):e91078.
    View in: PubMed
    Score: 0.045
  26. Solid pseudopapillary tumors of the pancreas: Specific pathological features predict the likelihood of postoperative recurrence. J Surg Oncol. 2016 Oct; 114(5):597-601.
    View in: PubMed
    Score: 0.043
  27. Intraductal papillary mucinous neoplasms of the pancreas with concurrent pancreatic and periampullary neoplasms. Eur J Surg Oncol. 2016 Feb; 42(2):197-204.
    View in: PubMed
    Score: 0.041
  28. Patterns of Recurrence After Resection of IPMN: Who, When, and How? Ann Surg. 2015 Dec; 262(6):1108-14.
    View in: PubMed
    Score: 0.041
  29. Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. Surgery. 2015 Nov; 158(5):1219-25.
    View in: PubMed
    Score: 0.040
  30. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg. 2015 May; 261(5):976-83.
    View in: PubMed
    Score: 0.040
  31. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. J Am Coll Surg. 2015 May; 220(5):839-44.
    View in: PubMed
    Score: 0.039
  32. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg. 2013 Sep; 258(3):466-75.
    View in: PubMed
    Score: 0.035
  33. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Pancreatology. 2012 Jul-Aug; 12(4):358-63.
    View in: PubMed
    Score: 0.032
  34. Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts. Ann Surg. 2011 Dec; 254(6):977-83.
    View in: PubMed
    Score: 0.031
  35. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res. 2009 Oct 15; 15(20):6412-20.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.